MASLD in Obesity: Causes, Risks, and Treatment Options

MASLD stands for metabolic dysfunction-associated steatotic liver disease. It is diagnosed when imaging or biopsy shows fat in the liver plus at least one cardiometabolic risk factor (obesity, type 2 diabetes, hypertension, or dyslipidemia), with alcohol use and other liver diseases excluded. MASH (metabolic dysfunction-associated steatohepatitis) is the inflammatory, more damaging subtype of MASLD, formerly called NASH. These terms replaced NAFLD/NASH in the 2023 multi-society nomenclature update, and the change was substantive, not cosmetic: the new definition requires a metabolic risk factor to be present, tying the diagnosis explicitly to metabolic disease rather than to fat alone. This article is about MASLD as it occurs in people with obesity, and how that differs from MASLD in people with normal body weight, diabetes, or after menopause.

The core claim, stated plainly

Obesity, particularly visceral (abdominal) fat, is the dominant driver of MASLD because expanded visceral fat releases free fatty acids and inflammatory signaling molecules directly into the portal circulation that feeds the liver. This mechanism is well established in metabolic and hepatology literature. What is not equally well established is a precise, generalizable prevalence number for "MASLD in obesity" that applies across populations, because estimates vary by diagnostic method (ultrasound versus MRI versus biopsy), population studied, and BMI cutoff used. Readers should treat any single percentage figure for prevalence as a range estimate from a specific study population, not a universal constant.

Why obesity drives liver fat accumulation

Visceral adipose tissue is metabolically active tissue, not passive storage. In obesity, especially central obesity, adipocytes release excess free fatty acids through lipolysis and increase secretion of pro-inflammatory signaling proteins while reducing protective adiponectin. The liver, which receives blood directly from the gut and visceral fat via the portal vein, is exposed to this fatty acid and cytokine load more than other organs. Inside the liver, this drives fat storage (steatosis), oxidative stress, and in a subset of patients, progression to inflammation and scarring (MASH and fibrosis).

Not everyone with steatosis progresses to MASH or fibrosis. People with obesity plus type 2 diabetes or dyslipidemia carry a materially higher risk of progressing to the fibrotic stages that determine long-term liver-related outcomes, but the biological reasons some patients progress and others do not are not fully mapped, and predicting an individual patient's trajectory from steatosis alone is not reliable with current tools.

How common is MASLD in people with obesity?

Research syntheses and cohort studies indicate that MASLD occurs far more frequently among individuals with obesity compared to the general population, with estimates typically ranging from 60 to 75 percent in those with BMI exceeding 30. However, the exact prevalence depends on how MASLD is defined and which populations are studied, and specific figures from earlier versions of this article lack verifiable sources and should not be cited as established fact. More reliably supported observations include the following: MASLD prevalence increases as BMI increases, rises further when additional metabolic syndrome criteria are met, and reaches particularly high levels in patients preparing for bariatric surgery, where liver biopsies obtained before the procedure show steatosis in the majority of candidates.

MASLD's clinical weight comes from its downstream consequences: it is a growing contributor to cirrhosis, liver-related mortality, and hepatocellular carcinoma, and MASLD-related liver disease has become one of the more common indications cited for liver transplant evaluation in some regions. Advanced fibrosis (stage F3 to F4) carries meaningfully higher liver-related mortality risk than early-stage disease (F0 to F1); the exact multiplier reported in different studies varies, and readers should treat any specific fold-increase number as needing verification against the primary study rather than as an established constant.

MASLD in type 2 diabetes: a higher-risk subgroup

Type 2 diabetes and MASLD frequently coexist, and the combination carries higher risk of fibrosis than obesity alone. Insulin resistance, the pathophysiologic link between the two conditions, keeps lipogenic pathways active in the liver even when the liver is already fat-saturated, and chronic hyperglycemia adds direct injury through glycation and altered lipid handling.

Clinical guideline bodies recommend that adults with type 2 diabetes be evaluated for MASLD and, if present, assessed for fibrosis using a non-invasive blood-based score such as FIB-4 (calculated from age, AST, ALT, and platelet count) rather than relying on liver enzymes alone, since a meaningful proportion of patients with significant fibrosis have normal ALT. A recent 2026 systematic review and meta-analysis evaluated empagliflozin, an SGLT2 inhibitor originally approved for diabetes, specifically in MASLD and reported benefit on liver-related outcomes in the populations studied (empagliflozin in MASLD systematic review and meta-analysis, 2026). This is a systematic review of trial-level evidence, not a regulatory approval, and SGLT2 inhibitors do not currently carry an FDA indication for MASLD or MASH; any use for liver disease specifically is off-label and should be discussed with a treating clinician rather than self-initiated.

Pioglitazone has trial evidence supporting histologic improvement in NASH, most notably in patients with diabetes or prediabetes, though it carries known tradeoffs including weight gain and fluid retention that require monitoring. GLP-1 receptor agonists (see below) are increasingly used in this subgroup because they address weight, glycemic control, and liver fat together, though head-to-head comparisons against pioglitazone in this specific population are limited.

MASLD in postmenopausal women

Estrogen appears to be protective against hepatic fat accumulation, likely in part through effects on liver lipid-handling genes. Before menopause, women tend to have lower MASLD prevalence than age-matched men; after menopause, this gap narrows, and several observational studies report postmenopausal MASLD prevalence approaching or exceeding that of men in the same age range, even after adjusting for BMI. The magnitude of this shift varies by study population, and readers should not treat any single percentage difference as a fixed, universal figure without checking the underlying cohort.

Whether menopausal hormone therapy meaningfully improves liver outcomes is not established. Observational data suggest an association between estrogen exposure and lower hepatic fat, but no randomized trial has used liver histology as its primary endpoint, so this remains a plausible but unproven benefit. Any decision about hormone therapy should weigh cardiovascular and breast cancer risk according to current menopause-specific guidance, not a liver-related rationale alone, and should be made with a clinician familiar with the patient's full risk profile.

Lean MASLD: a population that is easy to miss

MASLD does occur in people with a normal BMI (under 25 kg per m², or lower thresholds in some Asian populations), and this group is not a rare curiosity. Lean MASLD shares the same core biology as MASLD in obesity: insulin resistance and visceral fat accumulation can occur even when total body weight is normal, and genetic variants such as PNPLA3 increase risk independent of BMI. Because these patients often do not fit the clinical stereotype of a fatty liver patient, screening is more likely to be missed in primary care.

Management in lean patients cannot rely primarily on weight loss as the lever, since there is often little weight to lose. Dietary pattern (reducing refined carbohydrate and fructose intake, following a Mediterranean-style diet), genetic evaluation when the clinical picture is atypical, and pharmacologic treatment based on fibrosis stage rather than BMI are the more relevant strategies. Resmetirom's pivotal trial data suggest benefit that does not appear to depend on baseline BMI subgroup, though independent replication and real-world data in lean patients specifically remain limited.

Living with a MASLD diagnosis

Beyond biology, a diagnosis of MASLD raises practical and emotional questions that are easy to overlook in a purely mechanistic discussion: how to interpret a "fatty liver" finding found incidentally on imaging, how much lifestyle change is realistic and sustainable, and where to get ongoing support. A 2026 qualitative study of adults living with MASLD found that patients frequently reported uncertainty about disease severity, a felt stigma around the "fatty liver" label, and unmet needs for structured support in making sustained lifestyle changes (lived experience and support needs in adults with MASLD, 2026). This kind of evidence does not change the biological treatment algorithm, but it is a relevant reminder that a MASLD diagnosis should come with a clear explanation of severity, next steps, and where to find follow-up, not just a lab value.

Current and emerging treatment options

No single treatment fits every MASLD patient. Selection depends on fibrosis stage, presence of diabetes, and BMI, and should be guided by a clinician who has reviewed the patient's fibrosis staging.

Resmetirom (brand name Rezdiffra). FDA-approved in March 2024 for adults with MASH and moderate to severe fibrosis (stages F2 to F3), based on a pivotal trial showing a meaningfully higher rate of NASH resolution without worsening fibrosis compared with placebo. This is the first drug specifically approved for a MASLD-related histologic endpoint in the United States. It is not approved for earlier-stage steatosis without fibrosis, and its FDA status should be verified against the current label before prescribing, since approvals and labeling can be updated.

GLP-1 receptor agonists. Liraglutide showed NASH resolution benefit over placebo in an early phase 2 trial, and semaglutide produces substantial weight loss with associated reductions in liver fat in trials designed primarily around weight and glycemic endpoints. Larger, MASLD-specific trials with liver histology as the primary endpoint are ongoing or recently completed; specific effect sizes attributed to these trials in earlier drafts of this article could not be verified against a checkable primary source and are not repeated here. GLP-1 agonists are FDA-approved for obesity and type 2 diabetes; use for liver histology specifically, outside of an approved MASH-related indication, should be understood as addressing a shared risk factor (weight, insulin resistance) rather than a liver-specific approval, unless the prescribing label states otherwise.

Pioglitazone. Trial evidence supports histologic NASH resolution, with the strongest data in patients with diabetes or prediabetes. Weight gain and fluid retention are known tradeoffs requiring monitoring.

Vitamin E. Trial data support benefit in non-diabetic MASH patients specifically, but vitamin E carries long-term safety questions at high doses (including signals around all-cause mortality and hemorrhagic stroke in some analyses), which limits its use to carefully selected non-diabetic patients under clinician guidance rather than as an over-the-counter self-treatment.

Obeticholic acid. This agent did not receive FDA approval for NASH after review of its pivotal trial data; its regulatory status has changed over time and should be checked directly against current FDA records before being described as available or pending.

Bariatric or metabolic surgery. For patients with more severe obesity and MASLD-related comorbidities, bariatric surgery is associated with substantial rates of NASH resolution and fibrosis regression in prospective cohort studies, representing one of the more effective interventions currently available, though it carries its own surgical risks and is not appropriate for every patient.

SGLT2 inhibitors (such as empagliflozin). Originally developed for type 2 diabetes, this drug class has now been evaluated specifically in MASLD populations. A 2026 systematic review and meta-analysis found reductions in liver-related measures across the trials included (empagliflozin in MASLD, 2026). This is systematic-review-level evidence for an off-label liver use; SGLT2 inhibitors are not currently FDA-approved for MASLD or MASH specifically.

Lifestyle modification remains the foundation

Weight loss through diet and exercise is the most broadly applicable intervention for MASLD regardless of subgroup. A commonly cited threshold is that roughly 7 percent body weight loss produces measurable steatosis regression, and larger losses (around 10 percent or more) are associated with NASH resolution and fibrosis improvement in some patients, based on pooled analyses of lifestyle intervention trials with paired liver biopsies. These are population-level associations from specific trial cohorts, not a guarantee for any individual patient, and readers should not interpret them as a prescription without clinical guidance on caloric targets appropriate to their own health status.

A Mediterranean-style dietary pattern has outperformed low-fat diets for liver fat reduction in head-to-head trials, plausibly through lower refined carbohydrate load and higher intake of monounsaturated fat and polyphenols. Resistance and aerobic exercise both reduce liver fat, in some studies independent of weight change, suggesting that exercise has a direct metabolic effect on the liver beyond calorie deficit alone. Coffee consumption has been associated with lower fibrosis severity in multiple observational cohorts, though observational association is not the same as proven causal benefit, and this should be read as supportive context rather than a treatment recommendation.

Monitoring and when to seek specialist care

For adults with obesity, calculating a FIB-4 score (from age, AST, ALT, and platelet count, often available through a primary care visit) is a reasonable first non-invasive step to gauge fibrosis risk. A low FIB-4 score has a high negative predictive value for advanced fibrosis, meaning further invasive testing is often unnecessary in low-risk patients. A high FIB-4 score, or any indeterminate result in a patient with diabetes, warrants referral to a liver specialist and further imaging (MRI-based fat quantification or elastography) or consideration of biopsy.

A normal ALT does not rule out MASLD or MASH. Liver enzymes are frequently normal even in patients with significant fibrosis, which is part of why MASLD is widely underdiagnosed in primary care settings. Anyone with known MASLD who develops jaundice, new confusion, abdominal swelling, black or tarry stools, or signs of gastrointestinal bleeding should seek urgent medical care rather than waiting for a scheduled follow-up, since these can signal decompensated liver disease.

A subgroup-based decision framework for MASLD risk and next steps

This framework is meant to help a reader (or a clinician working through a new MASLD-adjacent finding) decide what to do next based on which subgroup applies. It does not replace individualized clinical assessment.

Step 1: Identify the dominant risk driver.

• Obesity with normal glucose tolerance → risk driver is likely visceral fat and insulin resistance; weight-focused intervention is first-line.
• Obesity plus type 2 diabetes → risk driver is compounded; fibrosis risk is higher than obesity alone; FIB-4 should be checked regardless of liver enzyme results.
• Normal BMI with metabolic risk factors present (dyslipidemia, central adiposity despite normal weight, family history) → consider lean MASLD; weight loss is not the primary lever; ask about genetic testing if the picture is atypical.
• Postmenopausal with new or worsening liver fat findings → consider estrogen loss as a contributing factor; do not assume hormone therapy is a liver treatment, since histologic benefit is unproven.

Step 2: Stage before treating. Fibrosis stage, not steatosis alone, should drive treatment intensity. A patient with simple steatosis and no fibrosis has a different risk profile and treatment menu than one with F2 to F3 fibrosis. FIB-4 (or a specialist-ordered elastography or MRI-based test) should come before any decision about pharmacologic therapy.

Step 3: Match treatment to stage and comorbidity, not to BMI category alone.

• No fibrosis, obesity present → lifestyle intervention (diet, exercise, weight loss target individualized with a clinician) is first-line; pharmacologic liver-specific treatment is not typically indicated at this stage.
• F2 to F3 fibrosis confirmed → resmetirom is FDA-approved for this specific indication; ask whether the diagnosing clinician has confirmed staging supports this approval.
• Type 2 diabetes present → discuss pioglitazone, GLP-1 agonists, and (as an off-label option under specialist guidance) SGLT2 inhibitors, weighing side-effect profiles.
• BMI over 35 with comorbidities and inadequate response to lifestyle and medical therapy → bariatric surgery evaluation is a reasonable next step.

Step 4: Recheck, do not assume permanence. Fibrosis stage and steatosis can improve or worsen. Re-testing (FIB-4 at minimum, imaging if available) roughly a year after starting an intervention is a reasonable interval to judge response, and any meaningful worsening should trigger specialist reassessment rather than continuing the same plan unchanged.

Where this framework runs out of evidence: it does not tell you your personal weight-loss target, does not substitute for biopsy-confirmed staging, and does not address rare secondary causes of steatosis (medication-induced, genetic storage disease) that require different workup entirely.

What is established, what is plausible, and what is not established

Established: obesity, and visceral fat in particular, is a major driver of MASLD through insulin resistance and lipotoxic injury to the liver. Weight loss reduces liver fat. Resmetirom is FDA-approved for MASH with F2 to F3 fibrosis. FIB-4 is a reasonable first non-invasive fibrosis screen. Type 2 diabetes increases fibrosis risk beyond obesity alone.

Plausible but not fully proven: that hormone therapy meaningfully improves liver histology in postmenopausal women; that specific numeric prevalence figures for MASLD in obesity, diabetes, or lean populations generalize precisely across all populations rather than reflecting the specific cohorts studied; the exact magnitude of benefit from newer GLP-1 or SGLT2-based regimens on liver histology outside their approved indications.

Not established from the material reviewed here: a reliable way to predict, at the individual level, which patients with simple steatosis will progress to fibrosis; a liver-specific approved indication for SGLT2 inhibitors or most GLP-1 agonists (as opposed to their approved diabetes/obesity indications); optimal long-term safety of high-dose vitamin E for this indication.